Skip to main content
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: Nature. 2017 Jun 21;547(7661):94–98. doi: 10.1038/nature22976

Figure 5. Mutagenesis validation and de novo TCR design.

Figure 5

a, Glycine scan of CDR3β of TCR025 (group II). Each mutant was stimulated by DRB1*1503-restricted Rv119515–29, as well as a CD3/CD28-positive control. Mean ± s.d. (n = 3, biological replicates) shown. b, Group II CDR3β sequences with common CDR3 length. c, Positional weight matrix (PWM) reports observed CDR3β positional amino acid frequencies from (b). d, Top 1,000 theoretical TCRs and scores from PWM (equation (5) in Methods). Top 10 predicted TCRs (De18–De09) shown in red. Natural TCRs obtained from donors shown in yellow. e, De18–De09 were stimulated by DRB1*1503-restricted Rv119515–29. Blue indicates modified amino acids and red dash line indicates the basal activity. Mean ± s.d. (n = 3, biological replicates) shown. Activity compared to TCR025, *P < 0.01 two-tailed Student’s t-test.